SCHEMBL2988253

SCHEMBL2988253

Cc1cccc(S(=O)(=O)c2ccc(-c3ccnc(NCCN4C(=O)NC(=O)C4(C)C)n3)s2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
HTR6 P50406 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
MAPK3 P27361 1/20 0.33
MAPK1 P28482 1/20 0.33
IKBKB O14920 1/20 0.33
DKK1 O94907 1/20 0.33
GSK3B P49841 1/20 0.33
RAF1 P04049 7/20 0.33
CDK2 P24941 2/20 0.33
CCNT1 O60563 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK7 P50613 1/20 0.33
CDK9 P50750 1/20 0.33
CCNH P51946 1/20 0.33
CCNA1 P78396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2980290 0.91 AKT3 (0.34) MAPK3MAPK1IKBKBDKK1GSK3B
SCHEMBL2980876 0.90 IKBKB (0.37) POLBPIK3CAMTORMAPK3MAPK1
SCHEMBL2986673 0.89 IKBKB (0.35) HTR6MAPK3MAPK1IKBKBDKK1
SCHEMBL2983034 0.86 AKT3 (0.36) PIK3CAMTORIKBKBDKK1GSK3B
SCHEMBL2980080 0.85 PIK3CA (0.34) POLBPIK3CAMTORMAPK3MAPK1
SCHEMBL2977566 0.84 BRAF (0.40) PIK3CAMTORIKBKBRAF1CDK2
SCHEMBL2975793 0.83 LOXL2 (0.37) KMT2APIK3CAMTORMAPK3MAPK1
SCHEMBL2983838 0.82 PIK3CA (0.35) PIK3CAMAPK3MAPK1RAF1CDK2
SCHEMBL2982199 0.81 MAP3K5 (0.35) POLBKMT2AMAPK3MAPK1IKBKB
SCHEMBL2975976 0.81 DKK1 (0.41) MAPK3MAPK1IKBKBDKK1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 US disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 POLB 16/4885KMT2A 1112/4885HTR6 2650/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 POLB 16/4885KMT2A 1112/4885HTR6 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.